Paper23800114
Clinicopathological correlates and prognostic significance of KRAS mutation status in a pooled prospective cohort of epithelial ovarian cancer.
Nodin B and 3 others. Diagn Pathol, 2013. Cited by 33 papers, by iCite.
Cite this record
ConductScience Library. Clinicopathological correlates and prognostic significance of KRAS mutation status in a pooled prospective cohort of epithelial ovarian cancer. Papers, record 23800114. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/23800114
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Clinicopathological correlates and prognostic significance of KRAS mutation status in a pooled prospective cohort of epithelial ovarian cancer.
- PubMed
Topics16
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Mutation | Major topic |
| Neoplasms, Glandular and Epithelial | Major topic |
| Ovarian Neoplasms | Major topic |
| Proto-Oncogene Proteins | Major topic |
| ras Proteins | Major topic |
| Adenocarcinoma, Mucinous | |
| Aged | |
| Biomarkers, Tumor | |
| Carcinoma, Ovarian Epithelial | |
| Female | |
| Humans | |
| Kaplan-Meier Estimate | |
| Middle Aged | |
| Prognosis | |
| Prospective Studies | |
| Proto-Oncogene Proteins p21(ras) |
Source PubMed
References49
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 21804916 | RBM3-regulated genes promote DNA integrity and affect clinical outcome in epithelial ovarian cancer. | Transl Oncol | 2011 | https://conductscience.org/library/papers/21804916 | PubMed |
| 2 | 21716157 | Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis. | Pathology | 2011 | https://conductscience.org/library/papers/21716157 | PubMed |
| 3 | 3047672 | KRAS codon 12 mutations occur very frequently in pancreatic adenocarcinomas. | Nucleic Acids Res | 1988 | https://conductscience.org/library/papers/3047672 | PubMed |
| 4 | 20126258 | Global regulator SATB1 recruits beta-catenin and regulates T(H)2 differentiation in Wnt-dependent manner. | PLoS Biol | 2010 | https://conductscience.org/library/papers/20126258 | PubMed |
| 5 | 8429286 | The Malmo Diet and Cancer Study. Design and feasibility. | J Intern Med | 1993 | https://conductscience.org/library/papers/8429286 | PubMed |
| 6 | 16806438 | KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants. | Gynecol Oncol | 2006 | https://conductscience.org/library/papers/16806438 | PubMed |
| 7 | 11444200 | k-ras mutation may be an early event in mucinous ovarian tumorigenesis. | Int J Gynecol Pathol | 2001 | https://conductscience.org/library/papers/11444200 | PubMed |
| 8 | 19358724 | KRAS mutation analysis in ovarian samples using a high sensitivity biochip assay. | BMC Cancer | 2009 | https://conductscience.org/library/papers/19358724 | PubMed |
| 9 | 12644542 | Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. | J Natl Cancer Inst | 2003 | https://conductscience.org/library/papers/12644542 | PubMed |
| 10 | 21571648 | Histologic, molecular, and cytogenetic features of ovarian cancers: implications for diagnosis and treatment. | Radiographics | 2011 | https://conductscience.org/library/papers/21571648 | PubMed |
| 11 | 22322322 | Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological features. | Virchows Arch | 2012 | https://conductscience.org/library/papers/22322322 | PubMed |
| 12 | 15111296 | Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. | Am J Pathol | 2004 | https://conductscience.org/library/papers/15111296 | PubMed |
| 13 | 8115781 | Residual tumor (R) classification and prognosis. | Semin Surg Oncol | 1994 | https://conductscience.org/library/papers/8115781 | PubMed |
| 14 | 19542870 | Pathogenetic pathways in ovarian endometrioid adenocarcinoma: a molecular study of 29 cases. | Am J Surg Pathol | 2009 | https://conductscience.org/library/papers/19542870 | PubMed |
| 15 | 12509763 | Targeting RAS signalling pathways in cancer therapy. | Nat Rev Cancer | 2003 | https://conductscience.org/library/papers/12509763 | PubMed |
| 16 | 22992394 | Expression of the global regulator SATB1 is an independent factor of poor prognosis in high grade epithelial ovarian cancer. | J Ovarian Res | 2012 | https://conductscience.org/library/papers/22992394 | PubMed |
| 17 | 22995373 | Immunohistochemistry with apoptotic-antiapoptotic proteins (p53, p21, bax, bcl-2), c-kit, telomerase, and metallothionein as a diagnostic aid in benign, borderline, and malignant serous and mucinous ovarian tumors. | Diagn Pathol | 2012 | https://conductscience.org/library/papers/22995373 | PubMed |
| 18 | 21870058 | Correlation of SATB1 overexpression with the progression of human rectal cancer. | Int J Colorectal Dis | 2012 | https://conductscience.org/library/papers/21870058 | PubMed |
| 19 | 9662379 | Tissue microarrays for high-throughput molecular profiling of tumor specimens. | Nat Med | 1998 | https://conductscience.org/library/papers/9662379 | PubMed |
| 20 | 17914554 | Prognostic value of estrogen receptor and progesterone receptor tumor expression in Danish ovarian cancer patients: from the 'MALOVA' ovarian cancer study. | Oncol Rep | 2007 | https://conductscience.org/library/papers/17914554 | PubMed |
Cited by23
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 33 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 39522047 | RAS signaling in carcinogenesis, cancer therapy and resistance mechanisms. | J Hematol Oncol | 2024 | https://conductscience.org/library/papers/39522047 | PubMed |
| 37851341 | Machine learning developed a PI3K/Akt pathway-related signature for predicting prognosis and drug sensitivity in ovarian cancer. | Aging (Albany NY) | 2023 | https://conductscience.org/library/papers/37851341 | PubMed |
| 36451660 | Role of RAS signaling in ovarian cancer. | F1000Res | 2022 | https://conductscience.org/library/papers/36451660 | PubMed |
| 34615547 | Identification and clinical significance of somatic oncogenic mutations in epithelial ovarian cancer. | J Ovarian Res | 2021 | https://conductscience.org/library/papers/34615547 | PubMed |
| 34301278 | Emerging strategies to target RAS signaling in human cancer therapy. | J Hematol Oncol | 2021 | https://conductscience.org/library/papers/34301278 | PubMed |
| 33817145 | Overexpression of RASAL1 Indicates Poor Prognosis and Promotes Invasion of Ovarian Cancer. | Open Life Sci | 2019 | https://conductscience.org/library/papers/33817145 | PubMed |
| 32782545 | Mutation analysis and genomic imbalances of cells found in effusion fluids from patients with ovarian cancer. | Oncol Lett | 2020 | https://conductscience.org/library/papers/32782545 | PubMed |
| 32120793 | Precision Medicine Tumor Boards: Clinical Applicability of Personalized Treatment Concepts in Ovarian Cancer. | Cancers (Basel) | 2020 | https://conductscience.org/library/papers/32120793 | PubMed |
| 32042390 | Prevalence of K-RAS mutations and CA125 tumor marker in patients with ovarian carcinoma. | Caspian J Intern Med | 2020 | https://conductscience.org/library/papers/32042390 | PubMed |
| 31111275 | KRAS status is related to histological phenotype in gastric cancer: results from a large multicentre study. | Gastric Cancer | 2019 | https://conductscience.org/library/papers/31111275 | PubMed |
| 31009485 | Arsenite malignantly transforms human prostate epithelial cells in vitro by gene amplification of mutated KRAS. | PLoS One | 2019 | https://conductscience.org/library/papers/31009485 | PubMed |
| 28728166 | Whole-genome sequencing revealed novel prognostic biomarkers and promising targets for therapy of ovarian clear cell carcinoma. | Br J Cancer | 2017 | https://conductscience.org/library/papers/28728166 | PubMed |
| 27995550 | Somatic Mutations in Prostate Cancer: Closer to Personalized Medicine. | Mol Diagn Ther | 2017 | https://conductscience.org/library/papers/27995550 | PubMed |
| 27893429 | MicroRNA-595 sensitizes ovarian cancer cells to cisplatin by targeting ABCB1. | Oncotarget | 2016 | https://conductscience.org/library/papers/27893429 | PubMed |
| 27231561 | Adenocarcinoma of Mullerian origin: review of pathogenesis, molecular biology, and emerging treatment paradigms. | Gynecol Oncol Res Pract | 2015 | https://conductscience.org/library/papers/27231561 | PubMed |
| 27048364 | Prognostic impact of tumour-associated B cells and plasma cells in epithelial ovarian cancer. | J Ovarian Res | 2016 | https://conductscience.org/library/papers/27048364 | PubMed |
| 26631045 | MicroRNA-613 inhibited ovarian cancer cell proliferation and invasion by regulating KRAS. | Tumour Biol | 2016 | https://conductscience.org/library/papers/26631045 | PubMed |
| 26170722 | Endometriosis and ovarian cancer: links, risks, and challenges faced. | Int J Womens Health | 2015 | https://conductscience.org/library/papers/26170722 | PubMed |
| 24889043 | Mutational status of KRAS, NRAS, and BRAF in primary clear cell ovarian carcinoma. | Virchows Arch | 2014 | https://conductscience.org/library/papers/24889043 | PubMed |
| 24848074 | Ovarian cancer in endometriosis: clinical and molecular aspects. | Minerva Ginecol | 2014 | https://conductscience.org/library/papers/24848074 | PubMed |
Genes11
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| AR | 367 | PubTator's text mining | https://conductscience.org/library/genes/367 | NCBI Gene |
| CHEK1 | 1111 | PubTator's text mining | https://conductscience.org/library/genes/1111 | NCBI Gene |
| CHEK2 | 11200 | PubTator's text mining | https://conductscience.org/library/genes/11200 | NCBI Gene |
| ESR1 | 2099 | PubTator's text mining | https://conductscience.org/library/genes/2099 | NCBI Gene |
| KRAS | 3845 | PubTator's text mining | https://conductscience.org/library/genes/3845 | NCBI Gene |
| MAP2K7 | 5609 | PubTator's text mining | https://conductscience.org/library/genes/5609 | NCBI Gene |
| MAPK1 | 5594 | PubTator's text mining | https://conductscience.org/library/genes/5594 | NCBI Gene |
| MCM3 | 4172 | PubTator's text mining | https://conductscience.org/library/genes/4172 | NCBI Gene |
| PGR | 5241 | PubTator's text mining | https://conductscience.org/library/genes/5241 | NCBI Gene |
| RBM3 | 5935 | PubTator's text mining | https://conductscience.org/library/genes/5935 | NCBI Gene |
| ZHX2 | 22882 | PubTator's text mining | https://conductscience.org/library/genes/22882 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/23800114
GET https://conductscience.org/api/papers/v1/23800114/references?page=2